Shanghai AbelZeta
Shanghai AbelZeta is a China-based cell therapy company running 2 late-stage cancer trials in hepatocellular carcinoma and multiple myeloma.
Overview
Shanghai AbelZeta, based in Shanghai, China, is a cell therapy company. AbelZeta Pharma is a global cell therapy company focused on discovering, developing and manufacturing CAR-T therapeutics for haematologic malignancies, inflammatory and immunological diseases, and solid tumours. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in hepatocellular carcinoma and multiple myeloma. The largest, NCT06590246 (A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)), plans to enrol 121 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyChongqing Precision Biotech
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyCatalYm
Shares Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyCelltrion
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyNanjing Leads Biolabs
Shares Hepatocellular carcinoma, Multiple myeloma and the tag ctgov-sponsor.
- CompanyAscentawits Pharmaceuticals
Shares Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyBioInvent International
Shares Hepatocellular carcinoma and the tag ctgov-sponsor.
- CompanyHangzhou Sumgen Biotech
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyLepu Biopharma
Shares Hepatocellular carcinoma and the tag ctgov-sponsor.